Adequan® Canine (polysulfated glycosaminoglycan) is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. Adequan® Canine is the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that is proven to inhibit cartilage loss in dogs’ synovial joints. Adequan® Canine helps to reduce joint inflammation (a primary cause of osteoarthritis pain), enhance the production of key cartilage components, and aid in the production of healthy synovial fluid. There is no generic version of Adequan® Canine. Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see the Full Prescribing Information.